|
Rapid Molecular Diagnostics INC | |
| |
|
|
|
|
|
The RMD tests have the following advantages:
|
RMD is in the process of making:
Strangles test for veterinary medicine
Helps prescribe correct antibiotics to horses which are treated for rhodococcus by symptom due to it's severity Allows non-infected horses to be removed from quarantine Allows for test results in a timely and cost effective manner |
|
Bacterial identification panel with resistance and suseptibility
Allows for inital sepsis bundle of care to contain narrow spectrum antibiotics by running a test at triage Allows for correct antibiotics to be administered assisting in antibiotic stewardship Allows for reduction in complications and further progression of disease by correct timely treatment Reduction in overall hospital stay and ICU admissions for SIRs |
|
Toxicology test for pain management
Allows for reduced time for toxicology screen to come back so that patients can recieve perscriptions sooner Allows for pain management clinics to run their own diagnostics achieving true Point of Care service |
RMD technology is dramatically different from other diagnostic technology by changing the fundemental detection and capture systems that are time consuming. In addition, due to wafer level manufacturing, the cost of production reduces the cost to the consumer significantly.
Generic Nanosensor Generic nanosensor allows for unparrelled flexibility and adaptability for the capture layer creating a true platform Ultra flat nanotechnology allows for heightened sensitivity when read by an ellipsometer Wafer Level manufacturing of 1000s of tests at once allows for a cheap consumable |
|
Ellipsometer A well known semiconductor instrument capable of measuring sub angstrom film thickness variations Can measure a test site in 50 miliseconds to 5 seconds |
|
Combined system Allows for rapid diagnostics to be performed Allows for high sensitivity tests to be performed Allows for cheap tests to be performed Allows for multiple different types of tests to be performed without new instrumentation |
The technology is protected by the patent "Sensor Device for Biosensing and Other Applications" US 2020/0348289 A1 owned by co-founders. All 18 claims were awarded in march 2022 and the patent will be finalized by the end of 2022.
|
|
Matthew, MS, is the Director of Research and Development at RMD. Mr. Maale has been the driving force behind the development of the ellipsometry-based diagnostic assays.
Matthew has designed and developed the diagnostic nanosensor, partially optimized the production of ultra-flat surface films, partially optimized hybridization conditions,
developed analytical models on the ellipsometer to assess thickness and refractive index, and generated preliminary data with CoV-2 probes and RNA.
Matthew received his B.S. in Mechanical Engineering from Texas Tech University in December, 2016 and recieved his Masters in 2020 from UTD in Biomedical Engineering.
|
|
Taralyn, MS, RMD's Director of Market Research has utilized her background in molecular immunology into the discovery market analysis for the identification and utilization of novel technologies.
She is highly organized and assists in detailed product planning, scheduling, maintaining timelines, preparing reports, communicating between team members, and other important tasks.
She has formally assisted in the preparation of information materials and website content, and in vetting potential GxP contract labs.
Taralyn received her B.S. in Biology from James Madison University in 2010, and Masters in Biotechnology from Mount Saint Marys University in 2016.
|
| |
|
Dr. Tobin, RMD's CEO, has led research and technical programs at BMI since 1999. Dr. Tobin has significant experience in project direction and management;
design, planning, and execution of research projects; personnel management; coordination of multi-site studies and development of research facilities.
Dr. Tobin fosters a highly interactive research and development group to apply the Company's proprietary technology, Immune Refocusing Technology,
to the design of antigens that induce broader protection against heterologous challenge. Dr. Tobin continues to maintain research projects and interests
in the development of broadened vaccines against human rhinovirus, RSV, poliovirus, influenza virus, HIV-1, and Acinetobacter baumannii. Dr. Tobin
is currently the Principal Investigator on two active NIH SBIR grants and one STTR contract at DTRA. Prior to joining BMI, Dr. Tobin was a Senior Scientist and Group Leader (Gene Expression Regulation Group) for SAIC-Frederick at the National Cancer Institute. While at the NCI, Dr. Tobin led projects related to development of virus-like particle (VLP) based vaccines for HIV-1, optimization of recombinant protein expression, development of animal models for AIDS and cancer, and investigations into the pathobiology and molecular mechanisms of bovine immunodeficiency virus (BIV) and visna virus. Dr. Tobin was a post-doctoral scientist applying transgenic mouse models to the understanding of oncogenesis in the laboratory of Dr. Terry Van Dyke. During his doctoral research, Dr. Tobin studied the replication of poliovirus with Dr. J. Bert Flanegan at the University of Florida. Prior to graduate studies, Dr. Tobin gained valuable insight into virology and research methods in the University of Virginia laboratory of Dr. Jay C. Brown and William W. Newcomb. | |
Rahul, RMD's VP of Engineering, joined Zyvex in 2001 to work on scaling down macro and meso size devices using MEMS and assembly. In this endeavor, Rahul has been PI on four
DARPA programs to build the world's smallest electron column, the World's smallest ion microcolumn, the system integrator for a brain stimulation and recording instrument, and
the developer of an implant for acute sensing during the critical phase of spinal cord injuries respectively. He is also the Director of MEMS, Nano Retina Inc and the system
architect for Bionic Eye-NR600, an innovation to heal the blind. Rahul has over 25 published articles and more than 10 patents awarded/pending in his name.
He is currently working on next generation Class III compliant neural transducers and, as adjunct faculty at University of Texas at Arlington, he has taught
advanced Graduate level courses in MEMS and MEMS design. In August 2018, Rahul Saini was awarded the Tech Titans Technology Inventors award.This award recognizes the pioneering accomplishments of a person, team or group responsible for the creation of breakthrough ideas, processes or products which have advanced the discipline(s) of the arts, education, electronics, energy, engineering, environment, medicine, and/or science. He was primarily recognized for his work on the NR-600 bionic eye.
Rahul has a BTech in Aerospace Engineering (1998) from the Indian Institute of Technology, Mumbai and an MS in Aerospace and Engineering Mechanics (
2001) from the University of Florida. |
| |
|
Dr. Gerhard Maale is the medical director of orthopedic oncology and leads the Complex Joints and Musculoskeletal Tumors Program
at the Dallas Forth Worth Sarcoma Group. He has more than 35 years of experience performing complex joint reconstructions and
treating bone and soft tissue disorders, bone disease, and musculoskeletal infections. After graduating from the University of Florida School of Medicine, he completed his
orthopedic surgery residency at the University of Virginia and an orthopedic oncology fellowship at the University of Florida. Dr. Maale has also published work in international
journals has six issued US patents and 7 patents pending. Dr. Maale is the Founder of Dallas Ft. Worth Sarcoma Group, the Director of Orthopedic Oncology, Medical City Plano, Texas, and the Director of Sara Canon Initiative for Sarcoma HCA Hospitals. He previous posiitons include: Associate Professor, Department of Orthopedic Surgery, Texas Tech University School of Medicine, Associate Professor, Department of Pathology, Texas Tech University School of Medicine, Director, Orthopedic Oncology Fellowship, University of Texas Southwestern Medical School, Dallas, Texas, and President, Dallas/Fort Worth Texas branch of Western Orthopedic Association, His many honors include: Recipient of the Journal of Trauma Residents' Award for the Northeast Regional Competition for NIH and NCI sponsored for Oncology Fellowship, Recipient of the State of Texas House of Representatives Certificate of Appreciation for Outstanding Contributions to the Fight Against Cancer, Teaching Excellence Award-Southwestern Orthopedic Residents, and Texas Tech health Science Center, El Paso, Texas Certificate of Appreciation. | |
John, Chief Strategy Officer of RMD, joined Zyvex Labs in March, 2001. Prior to Zyvex, John spent 15 years with Texas Instruments (TI) where he worked in
high resolution processing for
integrated circuits, MEMS, and quantum effect devices and also worked at MIT's Lincoln Laboratory on ion beam and x-ray lithography. John is Executive
VP at NanoRetina and currently lends his 30+ years of experience in micro- and nano-fabrication to his roles as Adjunct Professor at UT Dallas and Fellow
of the AVS, IEEE, and Micro Nano Engineering Society. He has attracted over $43M in research contracts to Zyvex and resulting products have grossed over
$80M. John has 114 published articles, more than 50 conference proceedings and other publications (>4200 citations) and 32 issued US Patents (>800 citations).
John has a B.S. (1975), M.S. (1977), PhD (1981) in Electrical Engineering from the University of Houston.
|
|
Rapid Molecular Diagnostics LLC
1301 North Plano Road
Contact us at: info@rapidmoleculardiagnostics.com
Contact Matthew Maale directly at: mmaale@rapidmoleculardiagnostics.com
Richardson, Texas, 75081